Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Andrew D.W. HillAndrew Hill Investment Advisors, Inc. | BiotechnologyBiotechnology | Andrew Hill Investment Advisors - VRTX Vertex Pharmaceuticals has caught the eye of investors as well. Vertex is developing... | NEUTRAL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Cliff GreenbergBaron Small Cap Fund | Vertiv Holdings Co $VRT• NYSE | Electrical EquipmentElectrical Equipment | Baron Small Cap Fund - VRT Vertiv Holdings Co provides power and cooling systems for data centers. Shares increased during... | NEUTRAL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Vulcan Value Partners LLCVulcan Value Partners Focus Plus | Investment Banking & BrokerageCapital Markets | Long VRTS (Virtus Investment Partners, Inc.) Virtus reported solid cash flow conversion and stable net fee rates alongside modest AUM growth. The company's distribution... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | C.T. FitzpatrickVulcan Value Partners - Small Cap | Investment Banking & BrokerageCapital Markets | Long VRTS (Virtus Investment Partners, Inc.) Virtus generated solid quarter-over-quarter AUM expansion while maintaining stable management fee realization. Excellent net-income-to-free-cash-flow conversion... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | C.T. FitzpatrickVulcan Value Partners - All Cap | Investment Banking & BrokerageCapital Markets | Long VRTS (Virtus Investment Partners, Inc.) Virtus Investment Partners posted steady low-single-digit AUM expansion, stable fee realizations, and strong conversion of net income to free cash flow. Distribution channel diversification... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Cassandra A. HardmanHardman Johnston Global Equity | Vertiv Holdings Co $VRT• NYSE | Electrical EquipmentElectrical Equipment | Long VRT (Vertiv Holdings Co) Shares in VRT outperformed after the company delivered a blowout Q4 earnings report, where orders significantly exceeded estimates. Earnings also beat... | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Vulcan Value Partners, LLCVulcan Value Partners - Focus | Investment Banking & BrokerageCapital Markets | Long VRTS (Virtus Investment Partners, Inc.) Virtus Investment Partners achieved steady AUM growth and stable fee realizations while expanding sales distribution channels. The company exhibits... | BULL | View Pitch → | |
| Feb 25, 2026 | Fund Letter | Dr. Hendrik LeberACATIS Investment | BiotechnologyBiotechnology | ACATIS Investment 2024 Q4 (VRTX) Vertex Pharmaceuticals has released disappointing data on its new pain relief medication, which is in clinical trials. It is supposed... | BULL | View Pitch → | |
| Jan 20, 2026 | Fund Letter | Cassandra A. HardmanHardman Johnston Global Equity | BiotechnologyBiotechnology | Hardman Johnston Global Equity 2025 Q4 (VRTX) Quarterly Liquidations: Vertex Pharmaceuticals Inc. BSD Analysis: Vertex is a rare biotech that prints cash like a consumer staples company. Cystic fibrosis dominance... | BULL | View Pitch → | |
| Jan 16, 2026 | Fund Letter | Cassandra A. HardmanHardman Johnston Global Equity | Vertiv Holdings Co $VRT• NYSE | Electrical EquipmentElectrical Equipment | Hardman Johnston Global Equity 2025 Q4 (VRT) We re-entered Vertiv Holdings Co. during the quarter. Demand for Vertiv's... | BULL | View Pitch → |
| Jan 8, 2026 | Fund Letter | Cassandra A. HardmanHardman Johnston Global Equity | BiotechnologyBiotechnology | Hardman Johnston Global Equity 2025 Q2 (VRTX) Vertex shares struggled after the company reported a Q1 top-line miss, driven by the one-time impact of a counterfeit version of their cystic fibrosis drug Trikafta in Russia. We do not... | BULL | View Pitch → | |
| Jan 8, 2026 | Fund Letter | Aziz HamzaogullariLoomis Sayles Global Growth Fund | BiotechnologyBiotechnology | Loomis Sayles Global Growth Fund 2025 Q2 (VRTX) Vertex Pharmaceuticals, founded in 1989, is a global biopharmaceutical company with deep expertise in protein and genetic science and a focus on specialty markets. The company is... | BULL | View Pitch → | |
| Dec 6, 2025 | Fund Letter | Derek PileckiGator Capital Management | Investment Banking & BrokerageCapital Markets | Gator Capital Management 2025 Q2 (VRTS) We believe Virtus Investment Partners offers a compelling investment from current levels. Virtus Investment Partners... | BULL | View Pitch → | |
| Dec 3, 2025 | Fund Letter | Amy ZhangAlger Mid Cap Focus Fund | Vertiv Holdings Co $VRT• NYSE | Electrical EquipmentElectrical Equipment | Alger Mid Cap Focus Fund 2025 Q2 (VRT) Vertiv specializes in critical cooling and power management infrastructure technologies, catering primarily to data center clients. As an industry... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.